तुलना करने के लिए मीट्रिक्स | ALSEN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधALSENपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.4x | −2.9x | −0.2x | |
PEG अनुपात | −0.40 | −0.02 | 0.00 | |
क़ीमत/बुक | 1.0x | 0.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 13.4x | 7.9x | 2.7x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 167.7% | 68.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.4% | 11.5% | अनलॉक करें |
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.